{"id":80391,"date":"2025-08-24T13:42:53","date_gmt":"2025-08-24T04:42:53","guid":{"rendered":"http:\/\/ic-clinic-ueno.com\/cutaneous-fibroma\/"},"modified":"2026-07-06T19:46:23","modified_gmt":"2026-07-06T10:46:23","slug":"cutaneous-fibroma","status":"publish","type":"page","link":"https:\/\/ic-clinic-ueno.com\/en\/treatment\/cutaneous-fibroma\/","title":{"rendered":"Dermatofibroma Treatment | IC Clinic Ueno"},"content":{"rendered":"\n

\u2728 What You Will Learn from This Article<\/h3>\n\n\n\n

\u2705 What dermatofibroma is and how it develops<\/mark>
\u2705 How to distinguish it from similar skin conditions<\/mark>
\u2705 Insurance-covered treatment options<\/mark>
\u2705 The risk of malignant transformation and the importance of early action<\/mark><\/p>\n\n\n\n

\ud83d\ude31 If left untreated\u2026<\/span>
\u26a0\ufe0f Spontaneous resolution occurs in only approximately 1\u20132% of cases<\/mark><\/span>
\u26a0\ufe0f Multiple lesions may indicate a possible autoimmune condition<\/mark><\/span>
\u26a0\ufe0f Although extremely rare, there is a risk of malignant transformation<\/mark><\/span><\/p>\n\n\n\n

\n
\ud83d\udcde Book a Consultation Now<\/a><\/div>\n<\/div>\n\n\n\n

\ud83d\udcad \u201cI have a small brown growth and don\u2019t know what to do.\u201d
\ud83d\ude30 \u201cIt doesn\u2019t hurt or itch, but I\u2019d like to have it removed if possible.\u201d<\/p>\n\n\n\n

Do any of these concerns sound familiar?<\/p>\n\n\n\n

A small brown growth on the skin may be caused by a skin condition called \u201cdermatofibroma.\u201d<\/mark> Because dermatofibroma is unlikely to resolve on its own, it is worth considering treatment at a clinic.<\/mark><\/p>\n\n\n\n

\ud83d\udcd6 This page explains the causes, symptoms, and treatment options for dermatofibroma. We encourage you to read on to better understand what may be causing the growth and what you can do about it.<\/p>\n\n\n\n

\ud83d\udd2c What Is Dermatofibroma? Causes and Symptoms<\/h2>\n\n\n\n

Dermatofibroma is a benign tumor that appears as a small, slightly raised, brownish bump on the skin<\/mark> [1,3,5].<\/p>\n\n\n\n

It is formally known as \u201cfibrous histiocytoma\u201d or \u201cdermatofibroma,\u201d and is among the more commonly encountered benign skin tumors<\/mark> [1,12].<\/p>\n\n\n\n

\ud83d\udca1 The growth is generally harmless, and while it may feel slightly unusual, it typically does not cause pain or itching<\/mark> [3,5].<\/p>\n\n\n\n

Histopathologically, it consists of a proliferation of fibroblasts and histiocytes accompanied by collagen fiber overgrowth [4,5].<\/p>\n\n\n\n

\ud83d\udd0d Key Diagnostic Feature<\/h3>\n\n\n\n

A characteristic \u201cdimple sign\u201d \u2014 in which the center of the lesion dimples inward when pinched \u2014 serves as a helpful diagnostic clue<\/mark> [5,10].<\/p>\n\n\n\n

\u26a0\ufe0f However, pinching the affected area may cause discomfort in some cases.<\/p>\n\n\n\n

\ud83d\udc65 Who Is Most Likely to Develop It?<\/h3>\n\n\n\n

Dermatofibroma most commonly develops on the arms and legs in adulthood [5,8].<\/p>\n\n\n\n

\ud83d\udcca It is particularly prevalent in women between their 20s and 40s, with a male-to-female ratio of approximately 1:2<\/mark> [5,13].<\/p>\n\n\n\n

\ud83d\udccd The lower extremities \u2014 especially the lower leg \u2014 are the most frequent site of occurrence, accounting for approximately 60\u201370% of all cases<\/mark> [8,13].<\/p>\n\n\n\n

\ud83d\udd22 Most people develop a single growth, though some individuals may develop multiple lesions.<\/p>\n\n\n\n

\ud83e\udd14 What Causes It?<\/h3>\n\n\n\n

The exact cause of dermatofibroma has not been fully established<\/mark> [5,19].<\/p>\n\n\n\n

\ud83e\udd9f Insect bites, minor injuries, and genetic factors are thought to play a role. Recent research suggests that dermatofibroma represents a reactive proliferation in response to trauma or other stimuli, and is more likely a reactive lesion rather than a true neoplasm<\/mark> [19].<\/p>\n\n\n\n

There are also reports indicating clonal proliferation, and the etiology remains a subject of ongoing discussion [19].<\/p>\n\n\n\n

\ud83c\udd9a How Dermatofibroma Differs from Similar Skin Conditions<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

The following skin conditions can look similar to dermatofibroma:<\/p>\n\n\n

\n
\ud83c\udfe5 Condition<\/th>\u2728 Characteristics<\/th><\/tr>
\ud83d\udc8a Epidermoid Cyst (Atheroma)<\/th>A tumor that forms when dead skin cells and sebum accumulate inside a sac beneath the skin<\/mark><\/td><\/tr>
\ud83e\uddf4 Lipoma<\/th>A soft tumor that forms from an accumulation of fat tissue<\/mark><\/td><\/tr>
\ud83d\udd2c Granuloma<\/th>A tumor that forms in response to foreign material or other substances that enter the body<\/mark><\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n

Below, we explain how each condition differs from dermatofibroma and how each is treated.<\/p>\n\n\n\n

\u2705 Please compare these descriptions with your own symptoms as a reference. Keep in mind that self-diagnosis can be difficult, so we also recommend consulting a clinic for a proper evaluation.<\/mark><\/p>\n\n\n\n

\ud83d\udc8a Epidermoid Cyst (Atheroma)<\/h3>\n\n\n\n

An epidermoid cyst is a tumor that forms when dead skin cells and sebum accumulate inside a sac beneath the skin.<\/mark><\/p>\n\n\n\n

The exact cause of epidermoid cysts is not fully understood.<\/p>\n\n\n\n

Dead skin cells and sebum that would normally shed from the skin surface accumulate inside the skin for unknown reasons, forming a pouch-like structure. A notable characteristic of epidermoid cysts is that they tend to grow larger if left untreated.<\/mark><\/p>\n\n\n\n

\ud83d\udd0d Unlike dermatofibroma, an epidermoid cyst typically has a dark central opening (punctum) and can grow considerably in size over time<\/mark> as the contents \u2014 sebum and dead skin cells \u2014 have no way to escape.<\/p>\n\n\n\n

For information on treatment options and costs for epidermoid cysts, please visit the following page:<\/p>\n\n\n\n

\ud83d\udc49 About Epidermoid Cysts (Atheroma)<\/a><\/p>\n\n\n\n

\ud83e\uddf4 Lipoma<\/h3>\n\n\n\n

A lipoma is a soft, benign tumor that forms from an accumulation of fat tissue.<\/mark><\/p>\n\n\n\n

Lipomas rarely cause pain or a sensation of firmness. However, depending on their location, they may press on nerves and cause numbness.<\/p>\n\n\n\n

\ud83d\udccf In terms of size, lipomas can be as small as around 1 cm or, in some cases, may exceed 10 cm.<\/mark><\/p>\n\n\n\n

\ud83d\udc68 They are most commonly seen in men between their 40s and 60s<\/mark> and tend to occur more frequently in people who are overweight or who have hyperlipidemia or diabetes.<\/p>\n\n\n\n

\ud83d\udd0d Unlike dermatofibroma, the skin over a lipoma may not change color.<\/mark><\/p>\n\n\n\n

The cause of lipomas is not fully understood. Because they are unlikely to resolve on their own, treatment is generally required for removal.<\/p>\n\n\n\n

For information on treatment options and costs for lipomas, please visit the following page:<\/p>\n\n\n\n

\ud83d\udc49 About Lipoma<\/a><\/p>\n\n\n\n

\ud83d\udd2c Granuloma<\/h3>\n\n\n\n

A granuloma is a tumor that develops as a result of prolonged inflammation.<\/mark><\/p>\n\n\n\n

It occurs when a foreign substance that has entered the body is not broken down over an extended period of time.<\/p>\n\n\n\n

\ud83e\udea8 Such foreign substances include sand, gravel, or other debris that enters the body through a wound. When the tumor is located near the surface of the skin, it may be identifiable by its appearance alone.<\/p>\n\n\n\n

\ud83c\udfe5 Imaging studies such as CT or MRI can be helpful in identifying the foreign material. Granulomas are treated by surgically removing the foreign substance and the tumor.<\/p>\n\n\n\n

\u26a0\ufe0f Unlike dermatofibroma, a granuloma can, in some cases, become malignant depending on the underlying cause.<\/mark><\/p>\n\n\n\n

\ud83d\udcb0 Dermatofibroma Can Be Treated with Insurance-Covered Surgery<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

\u2705 Dermatofibroma can be removed through surgical excision, which is covered by health insurance<\/mark> [7,12].<\/p>\n\n\n\n

\ud83d\udcca Complete excision is expected to provide a lasting resolution, with recurrence rates reported at approximately 5% or less when adequate surgical margins are secured<\/mark> [14].<\/p>\n\n\n\n

\u26a0\ufe0f In contrast, incomplete excision has been associated with recurrence rates of approximately 20\u201330%<\/mark>, making proper surgical technique an important consideration [14].<\/p>\n\n\n\n

\u23f1\ufe0f Procedure Duration and Discomfort<\/h3>\n\n\n\n

The duration of the procedure varies depending on the location and size of the growth, but it typically takes no more than around 20 minutes.<\/mark><\/p>\n\n\n\n

\ud83d\udc89 Local anesthesia is administered prior to the procedure, so patients can undergo treatment with minimal discomfort.<\/mark><\/p>\n\n\n\n

\u2728 About Scarring<\/h3>\n\n\n\n

After suture removal, a faint line-like scar may remain. However, the appearance of the scar tends to become less noticeable over time.<\/mark><\/p>\n\n\n\n

\ud83d\udca1 Since dermatofibroma does not pose a direct health risk, watchful waiting is also an option. If the growth is causing pain or itching, or if you are bothered by its appearance, surgical removal may be worth considering.<\/p>\n\n\n\n

\ud83c\udfaf Consult a Specialist First<\/h3>\n\n\n\n

\ud83d\ude0a We are happy to accommodate requests such as \u201cI\u2019d like to keep discomfort to a minimum\u201d or \u201cI\u2019d like the scarring to be as minimal as possible.\u201d<\/mark><\/p>\n\n\n\n

\ud83c\udfe5 Our clinic provides thorough examinations and treatment by physicians certified by the Japanese Society of Plastic and Reconstructive Surgery.<\/mark><\/p>\n\n\n\n

\n
\ud83d\udcdd Book a Consultation with a Specialist<\/a><\/div>\n<\/div>\n\n\n\n

\ud83d\udd2c Histopathological Subtypes<\/h2>\n\n\n\n

Several histopathological subtypes of dermatofibroma have been identified [14,15,17].<\/p>\n\n\n\n

\ud83d\udcda Major subtypes include cellular dermatofibroma, atrophic dermatofibroma, and monster cell dermatofibroma<\/mark>, each exhibiting distinct histological features [10,14,15].<\/p>\n\n\n\n

\ud83d\udcca Epidemiology and Prevalence of Dermatofibroma<\/h2>\n\n\n\n

Dermatofibroma accounts for approximately 10\u201315% of all benign skin tumors, making it a relatively common condition<\/mark> [1,13].<\/p>\n\n\n\n

\ud83d\udcc8 The annual incidence is estimated at approximately 3\u20135 cases per 100,000 people<\/mark>, with the highest prevalence among women in their 20s to 40s [5,13].<\/p>\n\n\n\n

\ud83d\udccd The lower extremities are the most common site of involvement, accounting for approximately 70% of cases<\/mark>, followed by the upper extremities and trunk [8,13].<\/p>\n\n\n\n

\ud83d\udd0d Diagnosis and Differential Diagnosis of Dermatofibroma<\/h2>\n\n\n\n

In diagnosing dermatofibroma, the characteristic \u201cdimple sign\u201d \u2014 central dimpling when the lesion is pinched \u2014 serves as an important clinical finding<\/mark> [5,10].<\/p>\n\n\n\n

\ud83d\udd2c Dermoscopy typically reveals central hyperpigmentation and a peripheral white reticular network<\/mark> [12].<\/p>\n\n\n\n

\u2695\ufe0f Differential diagnoses include dermatofibrosarcoma protuberans, neurofibroma, and hemangioma, and tissue biopsy for definitive diagnosis may be performed when necessary [3,9,24].<\/p>\n\n\n\n

\ud83e\uddec Histological Features and Classification<\/h2>\n\n\n\n

Histologically, dermatofibroma shows a mixed proliferation of fibroblasts and histiocytes accompanied by collagen fiber overgrowth [4,5].<\/p>\n\n\n\n

\ud83d\udd2c Immunohistochemically, it is characteristically positive for Factor XIIIa and partially positive for CD68<\/mark> [4].<\/p>\n\n\n\n

\ud83d\udcda Recognized histopathological subtypes include the cellular type, atrophic type, granular cell type, and monster cell type, each with distinct histological characteristics [10,14,15,17].<\/p>\n\n\n\n

\ud83d\udcc8 Post-Treatment Course and Prognosis<\/h2>\n\n\n\n

\u2705 The prognosis following complete excision is generally favorable, with recurrence rates of 5% or less when adequate surgical margins are secured<\/mark> [14].<\/p>\n\n\n\n

\u23f0 Post-operative scarring tends to become less noticeable over time, reaching its final appearance at around 6\u201312 months<\/mark> [7].<\/p>\n\n\n\n

\ud83d\udca1 Laser therapy and cryotherapy with liquid nitrogen are also available as treatment options; however, surgical complete excision is considered the first-line approach, as incomplete treatment may increase the risk of recurrence<\/mark> [12,14].<\/p>\n\n\n\n

\u2753 Frequently Asked Questions about Dermatofibroma<\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

Below are answers to frequently asked questions about dermatofibroma, covering topics such as the need for treatment and the risk of the condition worsening.<\/p>\n\n\n\n

Q. Will dermatofibroma symptoms resolve on their own?<\/strong>

Dermatofibroma is unlikely to resolve on its own, and there is a risk of recurrence even after it has improved<\/mark> [5,14].
\ud83d\udca1 The rate of spontaneous regression is extremely low at approximately 1\u20132%<\/mark>, and most cases show gradual enlargement over time [5].
\u26a0\ufe0f The likelihood of the tumor spreading to other areas is low; however, it may recur at the same site.
That said, tumors vary in nature, and it is not possible to state categorically that spontaneous resolution will not occur.<\/p> <\/div>

Q. Can dermatofibroma become malignant?<\/strong>

\u26a0\ufe0f Malignant transformation of dermatofibroma into dermatofibrosarcoma protuberans is extremely rare (less than 1%)<\/mark>, but has been reported [9,24,25].
\ud83d\udea8 If rapid growth, ulceration, or induration develops, early histological examination is recommended<\/mark> [9,24].
\ud83c\udfe5 Dermatofibrosarcoma protuberans is a condition our clinic identifies in a small number of cases each year.
\ud83d\udca1 Malignant transformation is very uncommon (approximately less than 1%), but caution is advised if rapid enlargement or ulceration is observed [9,24,25].
If the lesion is not bothersome and does not grow excessively, watchful waiting without active treatment may be an option.
\ud83d\ude0a Even with a benign tumor, if you have any concerns about its appearance, please consider consulting a clinic.<\/p> <\/div>

Q. Can dermatofibroma grow larger or develop in multiple locations?<\/strong>

\ud83d\udcca Cases have been documented in which more than 20 tumors developed simultaneously<\/mark>.
(Source: Three Cases of Multiple Dermatofibromas | J-STAGE<\/a>)
\u26a0\ufe0f When five or more dermatofibromas are present, the possibility of a concurrent autoimmune disease is considered higher<\/mark> [6].
\ud83c\udfe5 An association with systemic lupus erythematosus (SLE) in particular has been reported, with approximately 30\u201340% of multiple-lesion cases also having SLE<\/mark> [6,13].
\ud83d\udca1 In particular, co-occurrence with the inflammatory autoimmune condition systemic lupus erythematosus is frequently observed.<\/p> <\/div>

Q. Is laser treatment not suitable for dermatofibroma?<\/strong>

\u26a0\ufe0f Laser removal of the tumor tends to leave more noticeable scarring.<\/mark> This is because laser treatment can cause widespread damage to the dermis (the deeper layer of the skin).
\u2705 For this reason, surgical excision with a scalpel is the preferred treatment for dermatofibroma.<\/mark><\/p> <\/div> <\/div>\n\n\n\n

\u2728 Six Features of Our Clinic That Patients Appreciate<\/h2>\n\n\n\n

\ud83d\udc68\u200d\u2695\ufe0f Team-Based Care<\/mark>
Under the supervision of board-certified plastic surgeons certified by the Japanese Society of Plastic and Reconstructive Surgery, our clinic brings together specialist physicians from multiple disciplines, including plastic surgery, dermatology, and orthopedic surgery.<\/p>\n\n\n\n

\ud83d\udc89 Attention to Pain Management<\/mark>
Our specialist physicians select the most appropriate procedure from a wide range of surgical options, with the goal of minimizing discomfort during treatment.<\/p>\n\n\n\n

\u2728 Care for Post-Treatment Appearance<\/mark>
We approach every procedure with meticulous care to avoid unnecessary damage to the surrounding skin.<\/p>\n\n\n\n

\ud83c\udfe5 No Hospital Admission Required \u2014 Same-Day Surgery Available<\/mark>
From consultation to surgery, the process is smooth and efficient. Same-day surgery is available.<\/p>\n\n\n\n

\ud83d\ude89 Convenient Location<\/mark>
Our clinic is located just a 3-minute walk from major terminal stations in central Tokyo, including JR Shinjuku (South Exit) and JR Shibuya.<\/p>\n\n\n\n

\ud83d\udcb0 Insurance Coverage Available<\/mark>
Surgical excision of dermatofibroma at our clinic is covered by health insurance, so you can feel at ease regarding costs.<\/p>\n\n\n\n

\ud83d\ude0a Many patients visit our clinic with the following concerns.
Do any of these apply to you?<\/h3>\n\n\n\n

\u2705 Patients troubled by growths on the neck or face<\/mark>
\u2705 Patients worried about whether a growth might become malignant<\/mark>
\u2705 Patients who want to have a growth removed without leaving a scar<\/mark><\/p>\n\n\n\n

\ud83d\ude0a At our clinic, we are happy to accommodate requests such as \u201cI\u2019d like to keep discomfort to a minimum\u201d or \u201cI\u2019d like the scarring to be as minimal as possible.\u201d<\/mark><\/p>\n\n\n\n

\u23f1\ufe0f The procedure takes no more than around 20 minutes<\/mark>, keeping the burden on patients to a minimum. If you have any concerns about treating dermatofibroma, please feel free to reach out to us for a consultation.<\/p>\n\n\n\n

\n
\ud83c\udfaf Book Now for Peace of Mind<\/a><\/div>\n<\/div>\n\n\n\n

\ud83d\udcda References<\/h2>\n\n\n\n
    \n
  1. Japanese Dermatological Association, ed. Dermatology, 11th Edition<\/em>. Bunkodo, 2018.<\/li>\n\n\n\n
  2. Fletcher CDM, Unni KK, Mertens F, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, 2002.<\/li>\n\n\n\n
  3. Weiss SW, Goldblum JR. Enzinger and Weiss\u2019s Soft Tissue Tumors, 6th Edition. Elsevier, 2014.<\/li>\n\n\n\n
  4. Kamino H, Reddy VB, Pui J, et al. Fibrous histiocytoma and dermatofibroma: a comparative immunohistochemical study. J Cutan Pathol. 1992;19(5):364-370.<\/li>\n\n\n\n
  5. Zelger BW, Zelger BG, Burgdorf WH. Dermatofibroma\u2013a critical evaluation. Int J Surg Pathol. 2004;12(4):333-344.<\/li>\n\n\n\n
  6. Three Cases of Multiple Dermatofibromas. Skin Research<\/em>. 1998;40(4):369-373. J-STAGE.<\/li>\n\n\n\n
  7. Japanese Society of Plastic and Reconstructive Surgery, ed. Plastic Surgery, 4th Edition<\/em>. Kokseido Publishing, 2017.<\/li>\n\n\n\n
  8. Mentzel T, Kutzner H, Rutten A, et al. Benign fibrous histiocytoma (dermatofibroma) of the face: clinicopathologic and immunohistochemical study of 34 cases associated with an aggressive clinical course. Am J Dermatopathol. 2001;23(5):419-426.<\/li>\n\n\n\n
  9. Gleason BC, Fletcher CD. Dermatofibrosarcoma protuberans: a clinicopathologic review with emphasis on fibrosarcomatous areas. Am J Surg Pathol. 2007;31(7):1028-1036.<\/li>\n\n\n\n
  10. Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atrophic dermatofibroma. J Cutan Pathol. 2010;37(9):952-957.<\/li>\n\n\n\n
  11. Argenyi ZB, LeBoit PE, Santa Cruz D, et al. Nerve sheath myxoma (neurothekeoma) of the skin: light microscopic and immunohistochemical reappraisal of the cellular variant. J Cutan Pathol. 1993;20(4):294-303.<\/li>\n\n\n\n
  12. Japanese Dermatological Association. \u201cClinical Practice Guidelines for Skin Tumors, 2nd Edition,\u201d 2015.<\/li>\n\n\n\n
  13. Harii K, Hashimoto K, eds. NEW Dermatology, 3rd Edition<\/em>. Nakayama Shoten, 2018.<\/li>\n\n\n\n
  14. Calonje E, Mentzel T, Fletcher CD. Cellular benign fibrous histiocytoma: clinicopathologic analysis of 74 cases of a distinctive variant of cutaneous fibrous histiocytoma with frequent recurrence. Am J Surg Pathol. 1994;18(7):668-676.<\/li>\n\n\n\n
  15. Pan Y, Mentzel T, Kutzner H, et al. Dermatofibroma with monster cells: a clinicopathologic study of 57 cases and review of the literature. Am J Dermatopathol. 2006;28(4):312-318.<\/li>\n\n\n\n
  16. Kaddu S, Beham A, Cerroni L, et al. Cutaneous leiomyosarcoma. Am J Surg Pathol. 1997;21(9):979-987.<\/li>\n\n\n\n
  17. Tard\u00edo JC, Butr\u00f3n M, de la Cruz L, et al. Dermatofibroma with granular cell change: report of four cases. J Cutan Pathol. 2008;35(3):325-329.<\/li>\n\n\n\n
  18. Editorial Committee of the Japanese Journal of Dermatology. \u201cDiagnosis and Treatment of Dermatofibroma.\u201d Jpn J Dermatol<\/em>. 2017;127(8):1543-1558.<\/li>\n\n\n\n
  19. Chen TC, Kuo TT, Chan HL. Dermatofibroma is a clonal proliferative disorder. J Cutan Pathol. 2000;27(1):36-39.<\/li>\n\n\n\n
  20. Kutzner H, Mentzel T, Kaddu S, et al. Cutaneous angiosarcoma with foamy macrophages: a clinicopathologic study of 16 cases. Am J Dermatopathol. 2002;24(3):201-207.<\/li>\n\n\n\n
  21. Alguacil-Garcia A, Unni KK, Goellner JR. Malignant fibrous histiocytoma: an ultrastructural study of 15 cases. Cancer. 1978;42(5):2475-2487.<\/li>\n\n\n\n
  22. Dei Tos AP, Wadden C, Calonje E, et al. Immunohistochemical demonstration of glycoprotein p30\/32MIC2 (CD99) in synovial sarcoma: a potential cause of diagnostic confusion. Appl Immunohistochem. 1995;3(3):168-173.<\/li>\n\n\n\n
  23. Japanese Orthopaedic Association, ed. Orthopaedic Surgery, 4th Edition<\/em>. Bunkodo, 2020.<\/li>\n\n\n\n
  24. Hornick JL, Fletcher CD. Dermatofibrosarcoma protuberans: a critical review and update on pathology, genetics, and treatment. J Clin Pathol. 2006;59(7):682-690.<\/li>\n\n\n\n
  25. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow-up. Am J Surg Pathol. 2000;24(8):1125-1130.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    \u2728 What You Will Learn from This Article \u2705 What dermatofibroma is and how it develops\u2705 How to distinguish it from similar skin conditions\u2705 Insurance-covered treatment options\u2705 The risk of malignant transformation and the importance of early action \ud83d\ude31 If left untreated\u2026\u26a0\ufe0f Spontaneous resolution occurs in only approximately 1\u20132% of cases\u26a0\ufe0f Multiple lesions may indicate … <\/p>\n","protected":false},"author":0,"featured_media":0,"parent":79973,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_yoast_wpseo_focuskw":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_meta-robots-noindex":"","footnotes":""},"class_list":["post-80391","page","type-page","status-publish","entry","nothumb"],"acf":[],"_links":{"self":[{"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/pages\/80391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/comments?post=80391"}],"version-history":[{"count":3,"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/pages\/80391\/revisions"}],"predecessor-version":[{"id":82807,"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/pages\/80391\/revisions\/82807"}],"up":[{"embeddable":true,"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/pages\/79973"}],"wp:attachment":[{"href":"https:\/\/ic-clinic-ueno.com\/en\/wp-json\/wp\/v2\/media?parent=80391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}